What ENABLE-2 can do for you
ENABLE-2 is building an antibacterial drug discovery platform based on the learnings from ENABLE (IMI Innovative Medicines Initiative) with focus on the early stages of antibiotic discovery and development. ENABLE-2 is filling a gap, ensuring a complete global development pipeline for new antibiotics.
ENABLE-2 is supporting the development of direct acting systemic antibacterial compounds (potentiator molecules are also in scope, e.g. β-lactamase inhibitors). Pathogens in scope for ENABLE-2 are E. coli, K. pneumoniae, P. aeruginosa, A.baumannii, S. aureus and E. faecium (ESKAPE pathogens).
A second call is now open between December 20, 2022 and January 8, 2023. This call is open to Swedish research groups, including both academics and SMEs and to publicly funded universities in Europe.
The goal of ENABLE-2 is to develop Hits up to a level of advancement where they can successfully graduate to later stage initiatives (e.g., CARB-X, GARDP, REPAIR Impact Fund) or to out-licensing.
An initial call, open exclusively to Swedish research groups, including both academics and SMEs, was conducted October 4–31, 2021. In 2022, ENABLE-2 launched with four promising projects.
THIS IS ENABLE-2
Experimental platform with capabilities in chemistry, microbiology, ADME, safety and in vivo efficacy that will work with Hit owners to advance their compounds towards advanced Lead status. ENABLE-2 provides nondilutive experimental support to early stage antibiotic projects.
Expert knowledge hub The Portfolio Management Committee (PMC) of ENABLE-2 is composed of international/independent experts with broad antibacterial drug discovery and development experience. They will mentor your programme and advise on challenges as well as on how to mitigate liabilities.
Supports Hit owners acquire key missing data for PMC If your programme does not fully meet the thresholds for entry into the ENABLE-2 Platform there is a possibility of a Material Transfer Agreement (MTA) Route – a kind of pre-ENABLE-2 development package where this data could be generated.
Maintains data confidentiality ENABLE-2 adheres to a very restrictive communication policy and will only communicate what you agree upon or what is released by yourself.
Anders Karlén, Coordinator, Professor
Uppsala University (SE)
email@example.com, +46 (0)70-167 9177